Scientists are developing medications that replicate certain health benefits of physical activity to assist individuals with mobility challenges. The effort does not intend to replace exercise but instead offers options for those with frailty, disabilities, or long-term illnesses.
Physical activity enhances muscle strength, bone density, cardiovascular function, and mental well-being by activating a network of biochemical signals. Before creating effective drugs, researchers must pinpoint these pathways. The development process faces significant obstacles: more than 90% of experimental treatments fail in human testing, and approvals focus on treating specific diseases rather than general health improvements.
Read Also: Samsung expands massive South Korean chip complex
Thomas Burris, a pharmacologist at the University of Florida, investigates how exercise affects conditions such as obesity, type 2 diabetes, and neurodegenerative disorders. His group has examined a receptor in muscle tissue that stays active independently of movement. Exercise seems to strengthen this receptor, boosting stamina. Burris’s team synthesized a molecule that produces the same effect in mice, enabling them to endure longer physical exertion without prior training. Preliminary findings also indicate the compound may improve cognitive function and aid heart failure recovery.
Burris established the company Pelagos to move this research into human trials. Separately, Cambrian Bio announced in June that its experimental drug, ATX-304, increased metabolic activity and reduced visceral fat in patients with obesity and prediabetes. The medication activates energy-regulating pathways in cells, mirroring how exercise sustains endurance. Cambrian’s approach aims to prevent muscle wasting, a frequent side effect of weight-loss drugs such as GLP-1 agonists.
